Is acetazolamide (Diamox) safe for a woman at 27 weeks gestation?

Diamox Safety at 27 Weeks Pregnancy

Acetazolamide (Diamox) is generally NOT recommended during pregnancy, but may be considered at 27 weeks gestation when there is imminent risk of vision loss from idiopathic intracranial hypertension, after thorough risk-benefit discussion with the patient and obstetrician.

Guideline Recommendations

The 2018 consensus guidelines on idiopathic intracranial hypertension explicitly state that "with the limited evidence, it is difficult to make any safe recommendations on using acetazolamide during pregnancy and its manufacturers do not recommend its use" 1. The guidelines emphasize that a clear risk-benefit assessment must be discussed with the patient, noting that perinatal exposure in rodents has reported teratogenic effects 1.

FDA Drug Label Position

The FDA classifies acetazolamide as Pregnancy Category C, stating that it "has been shown to be teratogenic (defects of the limbs) in mice, rats, hamsters and rabbits" 2. The label clearly states: "Acetazolamide should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus" 2. There are no adequate and well-controlled studies in pregnant women 2.

Clinical Evidence from Human Studies

Despite the animal data and manufacturer warnings, the human evidence is more reassuring:

• Most recent prospective study (2024): Among 47 pregnancies in women with IIH, 8 participants were treated with acetazolamide with no increased risk of asphyxia, and all infants but one were healthy 3.

• Largest case series (2013): 50 pregnancies exposed to acetazolamide before 13 weeks gestation showed no major complications in offspring and spontaneous abortion rates similar to controls 4.

• Earlier case series (2005): 12 patients treated with acetazolamide during pregnancy had no adverse pregnancy outcomes 5.

When to Consider Use at 27 Weeks

At 27 weeks gestation (third trimester), the critical period of organogenesis has passed, which theoretically reduces teratogenic risk. Consider acetazolamide when:

• Active IIH with papilledema and progressive vision loss that threatens permanent visual impairment
• Conservative measures have failed (weight management, serial lumbar punctures)
• Surgical intervention (CSF diversion, optic nerve sheath fenestration) is being considered but acetazolamide may temporize the situation

Practical Management Algorithm

1. If IIH is stable or in remission: Avoid acetazolamide entirely
2. If mild worsening of symptoms (headache, tinnitus without vision threat): Use conservative management, serial lumbar punctures if needed 1
3. If imminent vision loss:
   • Multidisciplinary discussion with neurology, ophthalmology, and obstetrics
   • Consider serial lumbar punctures as temporizing measure 1
   • If acetazolamide needed: Full informed consent discussion, document risk-benefit analysis
   • Plan delivery at specialist center 1

Critical Caveats

• One case report (2016) described multiple congenital malformations (ectrodactyly, syndactyly, oligodontia) in a child exposed to 1,000 mg/day acetazolamide throughout pregnancy 6, though causation was not definitively established
• The lack of adverse outcomes in human studies may reflect selection bias - clinicians likely reserve acetazolamide for severe cases where benefit clearly outweighs risk
• Breastfeeding: If acetazolamide is used, a decision must be made whether to discontinue nursing or the drug 2

Bottom Line for 27 Weeks Gestation

At 27 weeks, you are past the period of major organogenesis. If vision is truly threatened and conservative measures have failed, acetazolamide can be used after documented informed consent discussion. However, if the patient has stable disease or only headache without papilledema and vision threat, acetazolamide should be avoided and alternative management pursued 1, 7.